^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Title:

LINC00963: A potential cancer diagnostic and therapeutic target

Published date:
04/21/2022
Excerpt:
Aberrantly upregulated LINC00963 was significantly associated with resistance to cisplatin/5-fluorouracil and oxaliplatin in oral squamous cell carcinoma and gastric cancer, respectively….LINC00963 is expected to become a new marker and therapeutic target of cancer.
DOI:
10.1016/j.biopha.2022.113019